Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) is expected to be releasing its earnings data before the market opens on Monday, May 12th. Analysts expect Unicycive Therapeutics to post earnings of ($0.14) per share for the quarter.
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). On average, analysts expect Unicycive Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Unicycive Therapeutics Stock Down 11.6 %
Shares of NASDAQ UNCY traded down $0.07 during mid-day trading on Friday, hitting $0.55. 1,799,186 shares of the company were exchanged, compared to its average volume of 1,460,932. The firm has a market cap of $65.86 million, a price-to-earnings ratio of -0.57 and a beta of 2.14. The stock has a 50 day simple moving average of $0.59 and a 200-day simple moving average of $0.61. Unicycive Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.16.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the stock. Guggenheim initiated coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They set a "buy" rating and a $6.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $7.50 target price on shares of Unicycive Therapeutics in a research report on Friday, April 11th.
Check Out Our Latest Analysis on UNCY
About Unicycive Therapeutics
(
Get Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Featured Articles
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
